Vortioxetine

A piperazine derivative that acts as a serotonin reuptake inhibitor, as a 5-HT3 receptor antagonist, and 5-HT1A receptor agonist. It is used for the treatment of anxiety and depression.

Also Known As:

Networked: 368 relevant articles (75 outcomes, 148 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Loft, Henrik: 19 articles (10/2021 - 06/2012)
2.	Mahableshwarkar, Atul R: 19 articles (01/2020 - 07/2012)
3.	Florea, Ioana: 18 articles (10/2021 - 07/2012)
4.	Jacobsen, Paula L: 16 articles (01/2022 - 03/2013)
5.	McIntyre, Roger S: 16 articles (01/2022 - 10/2014)
6.	Sanchez, Connie: 15 articles (11/2020 - 01/2014)
7.	Christensen, Michael Cronquist: 14 articles (01/2022 - 01/2017)
8.	Pehrson, Alan L: 11 articles (01/2018 - 01/2014)
9.	Chen, Yinzhong: 11 articles (11/2016 - 07/2012)
10.	Baldwin, David S: 8 articles (01/2022 - 07/2012)

Related Diseases

1.	Major Depressive Disorder (Major Depressive Disorders) 12/01/2016 - "A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms." 03/01/2015 - "Vortioxetine was significantly more effective than placebo for acute treatment of major depressive disorder (MDD). " 01/01/2017 - "The objectives of this meta-analysis of data from randomized, placebo-controlled studies were to assess the effect of vortioxetine on overall functioning (primary) and functional remission (secondary) using the Sheehan Disability Scale (SDS) in adults with major depressive disorder (MDD). " 01/01/2022 - "Practical Advice for Primary Care Clinicians on the Safe and Effective Use of Vortioxetine for Patients with Major Depressive Disorder (MDD)." 01/01/2022 - "Vortioxetine has demonstrated efficacy in randomized controlled trials and is approved for the treatment of major depressive disorder (MDD); however, data are limited concerning its effectiveness when used in routine clinical care. "
2.	Cognitive Dysfunction 07/01/2015 - "In this study of MDD adults who self-reported cognitive dysfunction, vortioxetine significantly improved cognitive function, depression, and functionality and was generally well tolerated." 05/31/2022 - "Our results suggest that vortioxetine might not be effective in reducing depressive symptoms or cognitive impairment in AD patients with depression. " 01/01/2019 - "Conclusion: Vortioxetine constitutes a promising treatment for treatment of cognitive impairment in MDD, but its place in the therapeutic armamentarium still needs to be determined." 11/01/2021 - "This study investigated the effects of vortioxetine on cognitive function in adults with mild cognitive impairment (MCI). " 01/01/2021 - "While this systematic review demonstrated promising procognitive effects from vortioxetine, the included studies did not enroll older adults, who are at the highest risk of cognitive impairment. "
3.	Anxiety Disorders (Anxiety Disorder) 12/01/2012 - "On assessing potential efficacy for vortioxetine in generalized anxiety disorder." 05/01/2014 - "Two studies supported the efficacy of vortioxetine in the treatment of generalized anxiety disorder and two do not. " 07/01/2012 - "The purpose of this study was to investigate the long-term maintenance of the efficacy of Lu AA21004 5 or 10 mg/day in the prevention of relapse in patients with generalized anxiety disorder (GAD). " 01/01/2019 - "Efficacy of vortioxetine in working patients with generalized anxiety disorder- ERRATUM." 01/01/2019 - "Efficacy of vortioxetine in working patients with generalized anxiety disorder."
4.	Neurobehavioral Manifestations 01/01/2022 - "Vortioxetine has been approved for the treatment of adults with MDD since 2013, and subsequent US label updates indicate that vortioxetine may be particularly beneficial for specific populations of patients with MDD, including those with treatment-emergent sexual dysfunction and patients experiencing certain cognitive symptoms. " 01/01/2022 - "In the Asian real-world setting, vortioxetine showed greater improvements in depressive and cognitive symptoms, work functioning, and response and remission rates when used as first-line versus second-line treatment or later. " 01/01/2020 - "Vortioxetine has also been shown to alleviate cognitive symptoms in preclinical studies and in patients with depression. " 02/01/2016 - "Furthermore, the positive effects of vortioxetine on improvement of cognitive symptoms of major depressive episodes are particularly well established in several clinical trials. " 01/01/2023 - "In routine clinical practice, vortioxetine was associated with clinically meaningful, sustained improvements in functioning, and depressive and cognitive symptoms, in patients with MDD and co-morbid GAD. "
5.	Anhedonia 01/01/2021 - "Vortioxetine showed significant short-term efficacy against anhedonia in this large population of patients with MDD. " 01/01/2019 - "Vortioxetine significantly improved anhedonia as evidenced by significant baseline to endpoint improvements in SHAPS and MADRS anhedonia factor scores (p < 0.0001). " 01/01/2023 - "Data from both studies confirm the safety and efficacy of flexibly dosed vortioxetine over 52 weeks of treatment and demonstrate that MADRS anhedonia factor scores continue to improve with long-term maintenance treatment." 01/01/2021 - "In the placebo-controlled studies, improvements in functioning associated with vortioxetine appeared to be mostly driven by the effect of treatment on MADRS anhedonia factors." 08/30/2023 - "Vortioxetine treatment had a particularly strong effect on the level of social anhedonia. "

Related Drugs and Biologics

1.	Antidepressive Agents (Antidepressants)
2.	Serotonin (5 Hydroxytryptamine)
3.	Duloxetine Hydrochloride (Cymbalta)
4.	Venlafaxine Hydrochloride (Effexor)
5.	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)
6.	Norepinephrine (Noradrenaline)
7.	Vortioxetine
8.	Escitalopram
9.	Desvenlafaxine Succinate
10.	Fluoxetine (Prozac)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Cognitive Training
3.	Secondary Prevention
4.	Activities of Daily Living (ADL)
5.	Transcranial Magnetic Stimulation